Bone Biologics Corp
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, 2024 · Year Ended December 31, 2023 | ||||
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | $(4,112,420) | $(8,948,731) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 188,819 | 152,599 | ||
| Change in fair value of warrant liability | (51,081) | (892,693) | ||
| Changes in operating assets and liabilities: | ||||
| Advances on research and development contract services | 70,785 | 251,066 | ||
| Prepaid expenses and other current assets | 104,171 | (5,335) | ||
| Accounts payable and accrued expenses | 89,780 | 255,876 | ||
| Research and development contract liabilities | - | (783,675) | ||
| Accrued legal settlement | (414,989) | 414,989 | ||
| Net cash used in operating activities | (4,124,935) | (9,555,904) | ||
| Cash flows from financing activities | ||||
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 1,504,113 | 5,044,161 | ||
| Exercise of pre-funded warrants | 662 | - | ||
| Proceeds from issuance of common shares under ATM offering, net of costs | 1,112,202 | - | ||
| Proceeds from issuance of common shares from warrant inducement, net of costs | 1,806,520 | - | ||
| Net cash provided by financing activities | 4,423,497 | 5,044,161 | ||
| Net increase (decrease) in cash | 298,562 | (4,511,743) | ||
| Cash, beginning of year | 3,026,569 | 7,538,312 | ||
| Cash, end of year | $3,325,131 | $3,026,569 | ||
| Supplemental information | ||||
| Interest paid - related party | $ | - | $ | - |
| Income taxes paid | $ | - | $ | - |
| Non-cash financing activities | ||||
| Options issued to settle accrued bonus | $77,400 | $ | - | |
| Deemed dividend – warrant inducement | $3,212,504 | $ | - | |
| Extinguishment of warrant liability upon exercise of warrants | $ | - | $711,024 | |
| Issuance of shares upon cashless exercise of warrants | $ | - | $11 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.